Business
InMed Updates Pain Program
InMed Updates Pain Program Canada NewsWire VANCOUVER, Oct. 17, 2017 CSE: I...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Updates Pain Program\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, Oct. 17, 2017\n\n\n\nCSE: INOTCQB: IMLFF\n\n\n\nVANCOUVER, Oct. 17, 2017 /CNW/ - InMed Pharmaceuticals, Inc. (\"InMed\" or the \"Company\") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today additional pre-clinical results in the development of INM-405 for the treatment of pain.\n\n\n \n \n\n \nIn recent pre-clinical testing, InMed employed several methods to verify the effects of individual, non-THC (tetrahydrocannabinol, the primary psychoactive ingredient in cannabis) cannabinoids, as well as a matrix of cannabinoid combinations, delivered to treat peripheral pain:\n\n\nin vivo animal models of pain to measure the pain tolerance;\nin vivo electrophysiology recordings to measure the blockage of pain signal transmission in the peripheral nerve fibres; and\nin vivo behavioral studies to verify the central nervous system (CNS) related side effects.\n\nResults from these studies suggest that peripheral application of certain cannabinoid compounds, alone or in combination, is effective in the treatment of craniofacial muscle pain disorders, without any observed CNS side effects, and may be a more desirable strategy than systemic pain-relief administration. Previously, InMed reported (NR August 20, 2015) the expression of both CB1 and CB2 receptors in trigeminal ganglion neurons innervating the masseter muscle, providing evidence that these receptors can be targets for craniofacial muscle pain.  CB1 and CB2 receptors are primary targets in the human body for cannabinoid drugs.\n\nThere is a need to find alternatives to treat chronic and severe pain that are non-addictive and have limited side effects. InMed continues to research the potential of non-THC cannabinoids to treat pain using a topical formulation. InMed's proof of concept study results published earlier this year in the European Journal of Pain (NR July 27, 2017) highlighte...